BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hasegawa S, Ikai I, Fujii H, Hatano E, Shimahara Y. Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complications. World J Surg. 2007;31:1256-1263. [PMID: 17453285 DOI: 10.1007/s00268-007-9001-y] [Cited by in Crossref: 129] [Cited by in F6Publishing: 124] [Article Influence: 9.2] [Reference Citation Analysis]
Number Citing Articles
1 Weber SM, Ribero D, O'Reilly EM, Kokudo N, Miyazaki M, Pawlik TM. Intrahepatic cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:669-680. [PMID: 26172134 DOI: 10.1111/hpb.12441] [Cited by in Crossref: 177] [Cited by in F6Publishing: 212] [Article Influence: 35.4] [Reference Citation Analysis]
2 Hahnvajanawong C, Sahakulboonyarak T, Boonmars T, Reutrakul V, Kerdsin A, Boueroy P. Inhibitory effect of isomorellin on cholangiocarcinoma cells via suppression of NF-κB translocation, the phosphorylated p38 MAPK pathway and MMP-2 and uPA expression. Exp Ther Med 2021;21:151. [PMID: 33456518 DOI: 10.3892/etm.2020.9583] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Nassour I, Mokdad AA, Porembka MR, Choti MA, Polanco PM, Mansour JC, Minter RM, Wang SC, Yopp AC. Adjuvant Therapy Is Associated With Improved Survival in Resected Perihilar Cholangiocarcinoma: A Propensity Matched Study. Ann Surg Oncol. 2018;25:1193-1201. [PMID: 29488187 DOI: 10.1245/s10434-018-6388-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
4 Oguro S, Esaki M, Kishi Y, Nara S, Shimada K, Ojima H, Kosuge T. Optimal indications for additional resection of the invasive cancer-positive proximal bile duct margin in cases of advanced perihilar cholangiocarcinoma. Ann Surg Oncol 2015;22:1915-24. [PMID: 25404474 DOI: 10.1245/s10434-014-4232-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
5 Krampitz GW, Aloia TA. Staging of Biliary and Primary Liver Tumors. Surgical Oncology Clinics of North America 2019;28:663-83. [DOI: 10.1016/j.soc.2019.06.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Kovalenko YA, Zharikov YO, Kukeev IA, Vishnevsky VA, Chzhao AV. [Predictors of outcomes in surgery for hilar cholangiocarcinoma]. Khirurgiia (Mosk). 2018;5-11. [PMID: 30531729 DOI: 10.17116/hirurgia20181015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 van der Gaag N, Kloek J, de Bakker J, Musters B, Geskus R, Busch O, Bosma A, Gouma D, van Gulik T. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Annals of Oncology 2012;23:2642-9. [DOI: 10.1093/annonc/mds077] [Reference Citation Analysis]
8 Yang M, Li WW, Chen JH, Cui MH, Liu JL. The value of caudate lobectomy in hilar cholangiocarcinoma treatment: A meta-analysis. Medicine (Baltimore) 2021;100:e24727. [PMID: 33607815 DOI: 10.1097/MD.0000000000024727] [Reference Citation Analysis]
9 Kimura N, Toyoki Y, Ishido K, Kudo D, Yakoshi Y, Tsutsumi S, Miura T, Wakiya T, Hakamada K. Perioperative blood transfusion as a poor prognostic factor after aggressive surgical resection for hilar cholangiocarcinoma. J Gastrointest Surg 2015;19:866-79. [PMID: 25605416 DOI: 10.1007/s11605-014-2741-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
10 Aljiffry M, Abdulelah A, Walsh M, Peltekian K, Alwayn I, Molinari M. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg. 2009;208:134-147. [PMID: 19228515 DOI: 10.1016/j.jamcollsurg.2008.09.007] [Cited by in Crossref: 148] [Cited by in F6Publishing: 137] [Article Influence: 11.4] [Reference Citation Analysis]
11 Valero V 3rd, Cosgrove D, Herman JM, Pawlik TM. Management of perihilar cholangiocarcinoma in the era of multimodal therapy. Expert Rev Gastroenterol Hepatol 2012;6:481-95. [PMID: 22928900 DOI: 10.1586/egh.12.20] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 4.5] [Reference Citation Analysis]
12 Utsumi M, Kitada K, Tokunaga N, Kato T, Narusaka T, Hamano R, Miyasou H, Tsunemitsu Y, Otsuka S, Inagaki M. A combined prediction model for biliary tract cancer using the prognostic nutritional index and pathological findings: a single-center retrospective study. BMC Gastroenterol 2021;21:375. [PMID: 34645392 DOI: 10.1186/s12876-021-01957-5] [Reference Citation Analysis]
13 Golse N, Nunez J, Mazzotta A, Cano L, Bergeat D, Sulpice L, Jeddou H, Abdelrafee A, Sa Cunha A, Cherqui D, Adam R, Boudjema K, Vibert E. Personalized Preoperative Nomograms Predicting Postoperative Risks after Resection of Perihilar Cholangiocarcinoma. World J Surg 2020;44:3449-60. [PMID: 32474628 DOI: 10.1007/s00268-020-05618-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Panayotova GG, Paterno F, Guarrera JV, Lunsford KE. Liver Transplantation for Cholangiocarcinoma: Insights into the Prognosis and the Evolving Indications. Curr Oncol Rep. 2020;22:49. [PMID: 32297105 DOI: 10.1007/s11912-020-00910-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
15 Mansini AP, Peixoto E, Jin S, Richard S, Gradilone SA. The Chemosensory Function of Primary Cilia Regulates Cholangiocyte Migration, Invasion, and Tumor Growth. Hepatology 2019;69:1582-98. [PMID: 30299561 DOI: 10.1002/hep.30308] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
16 Dumitrascu T, Brasoveanu V, Stroescu C, Ionescu M, Popescu I. Major hepatectomies for perihilar cholangiocarcinoma: Predictors for clinically relevant postoperative complications using the International Study Group of Liver Surgery definitions. Asian J Surg. 2016;39:81-89. [PMID: 26103932 DOI: 10.1016/j.asjsur.2015.04.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
17 Moreau J, Lapeyre M, Benoit C, Pezet D, Biau J. [Intra and extra hepatic cholangiocarcinomas radiation therapy]. Cancer Radiother 2021;25:175-81. [PMID: 33423966 DOI: 10.1016/j.canrad.2020.06.039] [Reference Citation Analysis]
18 Ecker BL, Vining CC, Roses RE, Maggino L, Lee MK, Drebin JA, Fraker DL, Vollmer CM, Datta J. Identification of Patients for Adjuvant Therapy After Resection of Carcinoma of the Extrahepatic Bile Ducts: A Propensity Score-Matched Analysis. Ann Surg Oncol. 2017;24:3926-3933. [PMID: 28952140 DOI: 10.1245/s10434-017-6095-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
19 Tang Z, Yang Y, Zhao Z, Wei K, Meng W, Li X. The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e11999. [PMID: 30142840 DOI: 10.1097/MD.0000000000011999] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
20 Kambakamba P, Deoliveira ML. Perihilar cholangiocarcinoma: paradigms of surgical management. The American Journal of Surgery 2014;208:563-70. [DOI: 10.1016/j.amjsurg.2014.05.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
21 Kow AW, Wook CD, Song SC, Kim WS, Kim MJ, Park HJ, Heo JS, Choi SH. Role of caudate lobectomy in type III A and III B hilar cholangiocarcinoma: a 15-year experience in a tertiary institution. World J Surg. 2012;36:1112-1121. [PMID: 22374541 DOI: 10.1007/s00268-012-1497-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
22 Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. J Gastrointest Surg. 2009;13:1470-1479. [PMID: 19421824 DOI: 10.1007/s11605-009-0900-0] [Cited by in Crossref: 72] [Cited by in F6Publishing: 65] [Article Influence: 6.0] [Reference Citation Analysis]
23 Popescu I, Dumitrascu T. Curative-intent surgery for hilar cholangiocarcinoma: prognostic factors for clinical decision making. Langenbecks Arch Surg 2014;399:693-705. [PMID: 24841192 DOI: 10.1007/s00423-014-1210-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 4.4] [Reference Citation Analysis]
24 Loehrer AP, House MG, Nakeeb A, Kilbane EM, Pitt HA. Cholangiocarcinoma: are North American surgical outcomes optimal? J Am Coll Surg 2013;216:192-200. [PMID: 23266423 DOI: 10.1016/j.jamcollsurg.2012.11.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
25 Chen XP, Lau WY, Huang ZY, Zhang ZW, Chen YF, Zhang WG, Qiu FZ. Extent of liver resection for hilar cholangiocarcinoma. Br J Surg. 2009;96:1167-1175. [PMID: 19705374 DOI: 10.1002/bjs.6618] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 4.6] [Reference Citation Analysis]
26 Giulianotti PC, Sbrana F, Bianco FM, Addeo P. Robot-assisted laparoscopic extended right hepatectomy with biliary reconstruction. J Laparoendosc Adv Surg Tech A. 2010;20:159-163. [PMID: 20201685 DOI: 10.1089/lap.2009.0383] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
27 Liu F, Hu HJ, Ma WJ, Wang JK, Ran CD, Regmi P, Li FY. Is radical resection of hilar cholangiocarcinoma plus partial resection of pancreatic head justified for advanced hilar cholangiocarcinoma? ANZ J Surg. 2020;90:1666-1670. [PMID: 32452116 DOI: 10.1111/ans.15955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Cidon EU. Resectable Cholangiocarcinoma: Reviewing the Role of Adjuvant Strategies. Clin Med Insights Oncol 2016;10:43-8. [PMID: 27199577 DOI: 10.4137/CMO.S32821] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
29 Xiang S, Lau WY, Chen XP. Hilar cholangiocarcinoma: controversies on the extent of surgical resection aiming at cure. Int J Colorectal Dis. 2015;30:159-171. [PMID: 25376337 DOI: 10.1007/s00384-014-2063-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 4.4] [Reference Citation Analysis]
30 Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E, Seo S, Terajima H, Uchida Y, Ajiki T, Satake H, Kamei K, Tohyama T, Hirose T, Ikai I, Morita S, Ioka T. A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208): Kansai Hepato-Biliary Oncology Group. Annals of Surgery 2019;270:230-7. [DOI: 10.1097/sla.0000000000002865] [Cited by in Crossref: 19] [Cited by in F6Publishing: 8] [Article Influence: 9.5] [Reference Citation Analysis]
31 Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA. The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre. Aliment Pharmacol Ther. 2010;31:625-633. [PMID: 20003093 DOI: 10.1111/j.1365-2036.2009.04218.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 63] [Article Influence: 1.6] [Reference Citation Analysis]
32 Ang C. Role of the fibroblast growth factor receptor axis in cholangiocarcinoma. J Gastroenterol Hepatol 2015;30:1116-22. [PMID: 25678238 DOI: 10.1111/jgh.12916] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
33 Zhang H, Shen F, Han J, Shen YN, Xie GQ, Wu MC, Yang T. Epidemiology and surgical management of intrahepatic cholangiocarcinoma. Hepat Oncol 2016;3:83-91. [PMID: 30191028 DOI: 10.2217/hep.15.34] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
34 Song YJ, Lim MC, Kang S, Seo SS, Kim SH, Han SS, Park SY. Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer. Gynecol Oncol. 2011;121:253-257. [PMID: 21277009 DOI: 10.1016/j.ygyno.2010.12.350] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
35 Yamanaka K, Hatano E, Kanai M, Tanaka S, Yamamoto K, Narita M, Nagata H, Ishii T, Machimoto T, Taura K, Uemoto S. A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer. Int J Clin Oncol 2014;19:485-9. [DOI: 10.1007/s10147-013-0578-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
36 Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T. Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 2009;250:950-6. [PMID: 19953713 DOI: 10.1097/sla.0b013e3181b0fc8b] [Cited by in Crossref: 82] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
37 Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15(34): 4240-4262 [PMID: 19750567 DOI: 10.3748/wjg.15.4240] [Cited by in CrossRef: 175] [Cited by in F6Publishing: 157] [Article Influence: 14.6] [Reference Citation Analysis]
38 Hu HJ, Mao H, Shrestha A, Tan YQ, Ma WJ, Yang Q, Wang JK, Cheng NS, Li FY. Prognostic factors and long-term outcomes of hilar cholangiocarcinoma: A single-institution experience in China. World J Gastroenterol 2016; 22(8): 2601-2610 [PMID: 26937148 DOI: 10.3748/wjg.v22.i8.2601] [Cited by in CrossRef: 38] [Cited by in F6Publishing: 37] [Article Influence: 7.6] [Reference Citation Analysis]
39 Song W, Miao DL, Chen L. Survival rates are higher in married patients with biliary tract cancer: a population-based study. Oncotarget 2018;9:9531-9. [PMID: 29507708 DOI: 10.18632/oncotarget.24170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
40 Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. J Clin Oncol. 2012;30:1934-1940. [PMID: 22529261 DOI: 10.1200/jco.2011.40.5381] [Cited by in Crossref: 384] [Cited by in F6Publishing: 175] [Article Influence: 42.7] [Reference Citation Analysis]
41 Koprowski S, Sokolowski K, Kunnimalaiyaan S, Gamblin TC, Kunnimalaiyaan M. Curcumin-mediated regulation of Notch1/hairy and enhancer of split-1/survivin: molecular targeting in cholangiocarcinoma. J Surg Res. 2015;198:434-440. [PMID: 25890434 DOI: 10.1016/j.jss.2015.03.029] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
42 Franzese C, Bonu ML, Comito T, Clerici E, Loi M, Navarria P, Franceschini D, Pressiani T, Rimassa L, Scorsetti M. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol 2020;146:2289-97. [PMID: 32524292 DOI: 10.1007/s00432-020-03285-9] [Reference Citation Analysis]
43 Jung JH, Lee HJ, Lee HS, Jo JH, Cho IR, Chung MJ, Park JY, Park SW, Song SY, Bang S. Benefit of neoadjuvant concurrent chemoradiotherapy for locally advanced perihilar cholangiocarcinoma. World J Gastroenterol 2017; 23(18): 3301-3308 [PMID: 28566890 DOI: 10.3748/wjg.v23.i18.3301] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
44 Zhou L, Luo X. Platelet to lymphocyte ratio in biliary tract cancer: Review and meta-analysis. Clinica Chimica Acta 2017;474:102-7. [DOI: 10.1016/j.cca.2017.09.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
45 Zhao HP, Zhang ZH, Zheng AH. Assessment of treatment outcomes in patients with advanced hilar cholangiocarcinoma (stages III-IV): Clinical significance of interventional therapy. Medicine (Baltimore). 2018;97:e11550. [PMID: 30278479 DOI: 10.1097/md.0000000000011550] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Hester C, Nassour I, Adams-huet B, Augustine M, Choti MA, Minter RM, Mansour JC, Polanco PM, Porembka MR, Wang SC, Yopp AC. Improved Survival in Surgically Resected Distal Cholangiocarcinoma Treated with Adjuvant Therapy: a Propensity Score Matched Analysis. J Gastrointest Surg 2018;22:2080-7. [DOI: 10.1007/s11605-018-3875-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
47 Noji T, Tsuchikawa T, Ebihara Y, Nakamura T, Kato K, Matsumoto J, Tanaka E, Shichinohe T, Hirano S. Post-operative depletion of platelet count is associated with anastomotic insufficiency following intrahepatic cholangiojejunostomy: a case-control study from the results of 220 cases of intrahepatic cholangiojejunostomy. BMC Surg 2014;14:81. [PMID: 25323783 DOI: 10.1186/1471-2482-14-81] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
48 Lee TC, Morris MC, Patel SH, Shah SA. Expanding the Surgical Pool for Hepatic Resection to Treat Biliary and Primary Liver Tumors. Surg Oncol Clin N Am 2019;28:763-82. [PMID: 31472918 DOI: 10.1016/j.soc.2019.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
49 Kloek JJ, Ten Kate FJ, Busch OR, Gouma DJ, van Gulik TM. Surgery for extrahepatic cholangiocarcinoma: predictors of survival. HPB (Oxford) 2008;10:190-5. [PMID: 18773053 DOI: 10.1080/13651820801992575] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
50 Li H, Li B, Wei Y. Hepatocellular carcinoma patients may benefit from left hemi-hepatectomy with caudate lobectomy. Pak J Med Sci 2013;29:249. [PMID: 24353553 DOI: 10.12669/pjms.291.3216] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 Sangkhamanon S, Jongpairat P, Sookprasert A, Wirasorn K, Titapun A, Pugkhem A, Ungareevittaya P, Chindaprasirt J. Programmed Death-Ligand 1 (PD-L1) Expression Associated with a High Neutrophil/Lymphocyte Ratio in Cholangiocarcinoma. Asian Pac J Cancer Prev 2017;18:1671-4. [PMID: 28670887 DOI: 10.22034/APJCP.2017.18.6.1671] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
52 Endo I, House MG, Klimstra DS, Gönen M, D'Angelica M, Dematteo RP, Fong Y, Blumgart LH, Jarnagin WR. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol 2008;15:2104-12. [PMID: 18543039 DOI: 10.1245/s10434-008-0003-2] [Cited by in Crossref: 81] [Cited by in F6Publishing: 67] [Article Influence: 6.2] [Reference Citation Analysis]
53 Saxena A, Chua TC, Chu FC, Morris DL. Improved outcomes after aggressive surgical resection of hilar cholangiocarcinoma: a critical analysis of recurrence and survival. Am J Surg. 2011;202:310-320. [PMID: 21871986 DOI: 10.1016/j.amjsurg.2010.08.041] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 5.1] [Reference Citation Analysis]
54 Kim E, Kim YJ, Kim K, Song C, Kim JS, Oh DY, Nam EM, Chie EK. Salvage radiotherapy for locoregionally recurrent extrahepatic bile duct cancer after radical surgery. Br J Radiol 2017;90:20170308. [PMID: 28937265 DOI: 10.1259/bjr.20170308] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
55 Akoad M, Jenkins R. Proximal biliary malignancy. Surg Clin North Am. 2008;88:1409-1428, x-xi. [PMID: 18992602 DOI: 10.1016/j.suc.2008.07.012] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
56 Skipworth JR, Olde Damink SW, Imber C, Bridgewater J, Pereira SP, Malagó M. Review article: surgical, neo-adjuvant and adjuvant management strategies in biliary tract cancer. Aliment Pharmacol Ther. 2011;34:1063-1078. [PMID: 21933219 DOI: 10.1111/j.1365-2036.2011.04851.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 58] [Article Influence: 5.6] [Reference Citation Analysis]
57 Goldaracena N, Gorgen A, Sapisochin G. Current status of liver transplantation for cholangiocarcinoma. Liver Transpl. 2018;24:294-303. [PMID: 29024405 DOI: 10.1002/lt.24955] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 12.7] [Reference Citation Analysis]
58 Koh M, Park JH, Yoo C, Yoon SM, Jung J, Ryoo BY, Chang HM, Kim KP, Jeong JH, Kim JH. Radiation therapy for recurrent extrahepatic bile duct cancer. PLoS One 2021;16:e0253285. [PMID: 34133471 DOI: 10.1371/journal.pone.0253285] [Reference Citation Analysis]
59 Al Mahjoub A, Menahem B, Fohlen A, Dupont B, Alves A, Launoy G, Lubrano J. Preoperative Biliary Drainage in Patients with Resectable Perihilar Cholangiocarcinoma: Is Percutaneous Transhepatic Biliary Drainage Safer and More Effective than Endoscopic Biliary Drainage? A Meta-Analysis. Journal of Vascular and Interventional Radiology 2017;28:576-82. [DOI: 10.1016/j.jvir.2016.12.1218] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 11.5] [Reference Citation Analysis]
60 Boueroy P, Aukkanimart R, Boonmars T, Sriraj P, Ratanasuwan P, Juasook A, Wonkchalee N, Vaeteewoottacharn K, Wongkham S. Inhibitory Effect of Aspirin on Cholangiocarcinoma Cells. Asian Pac J Cancer Prev 2017;18:3091-6. [PMID: 29172284 DOI: 10.22034/APJCP.2017.18.11.3091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Hyodo T, Kumano S, Kushihata F, Okada M, Hirata M, Tsuda T, Takada Y, Mochizuki T, Murakami T. CT and MR cholangiography: advantages and pitfalls in perioperative evaluation of biliary tree. Br J Radiol. 2012;85:887-896. [PMID: 22422383 DOI: 10.1259/bjr/21209407] [Cited by in Crossref: 70] [Cited by in F6Publishing: 43] [Article Influence: 7.8] [Reference Citation Analysis]
62 Wang K, Zhang H, Xia Y, Liu J, Shen F. Surgical options for intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6:79-90. [PMID: 28503555 DOI: 10.21037/hbsn.2017.01.06] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
63 Dumitrascu T, Chirita D, Ionescu M, Popescu I. Resection for hilar cholangiocarcinoma: analysis of prognostic factors and the impact of systemic inflammation on long-term outcome. J Gastrointest Surg. 2013;17:913-924. [PMID: 23319395 DOI: 10.1007/s11605-013-2144-2] [Cited by in Crossref: 52] [Cited by in F6Publishing: 51] [Article Influence: 6.5] [Reference Citation Analysis]
64 Capobianco I, Rolinger J, Nadalin S. Resection for Klatskin tumors: technical complexities and results. Transl Gastroenterol Hepatol. 2018;3:69. [PMID: 30363698 DOI: 10.21037/tgh.2018.09.01] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
65 Peixoto RD, Renouf D, Lim H. A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol 2014;5:428-32. [PMID: 25436121 DOI: 10.3978/j.issn.2078-6891.2014.081] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
66 Ferrero A, Russolillo N, Viganò L, Sgotto E, Lo Tesoriere R, Amisano M, Capussotti L. Safety of conservative management of bile leakage after hepatectomy with biliary reconstruction. J Gastrointest Surg. 2008;12:2204-2211. [PMID: 18642049 DOI: 10.1007/s11605-008-0586-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
67 Alanazi SA, Alanazi F, Haq N, Shakeel F, Badran MM, Harisa GI. Lipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application Prospects. Curr Drug Deliv 2020;17:826-44. [PMID: 32026776 DOI: 10.2174/1567201817666200206104338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
68 Bhardwaj N, Garcea G, Dennison AR, Maddern GJ. The Surgical Management of Klatskin Tumours: Has Anything Changed in the Last Decade? World J Surg 2015;39:2748-56. [PMID: 26133907 DOI: 10.1007/s00268-015-3125-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.6] [Reference Citation Analysis]
69 Zhang BY, Lu Y, Dong Q, Sun CD, Mu P. Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma. Am J Med Sci 2010;339:221-4. [PMID: 20220331 DOI: 10.1097/MAJ.0b013e3181c7c8b4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
70 Unno M, Katayose Y, Rikiyama T, Yoshida H, Yamamoto K, Morikawa T, Hayashi H, Motoi F, Egawa S. Major hepatectomy for perihilar cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2010;17:463-469. [PMID: 19941010 DOI: 10.1007/s00534-009-0206-3] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 5.8] [Reference Citation Analysis]
71 Lee HC, Lee JH, Lee SW, Lee JH, Yu M, Jang HS, Kim SH. Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer. Radiat Oncol J 2019;37:279-85. [PMID: 31918466 DOI: 10.3857/roj.2019.00430] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
72 Singh MK, Facciuto ME. Current management of cholangiocarcinoma. Mt Sinai J Med. 2012;79:232-245. [PMID: 22499494 DOI: 10.1002/msj.21298] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
73 Mansour JC, Aloia TA, Crane CH, Heimbach JK, Nagino M, Vauthey JN. Hilar cholangiocarcinoma: expert consensus statement. HPB (Oxford). 2015;17:691-699. [PMID: 26172136 DOI: 10.1111/hpb.12450] [Cited by in Crossref: 169] [Cited by in F6Publishing: 190] [Article Influence: 33.8] [Reference Citation Analysis]
74 Malago M, Frilling A, Li J, Lang H, Broelsch CE. Cholangiocellular carcinoma--the role of caudate lobe resection and mesohepatectomy. HPB (Oxford). 2008;10:179-182. [PMID: 18773050 DOI: 10.1080/13651820801992500] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
75 Kato Y, Takahashi S, Gotohda N, Konishi M. Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer. J Gastrointest Surg 2016;20:1435-43. [PMID: 27250990 DOI: 10.1007/s11605-016-3180-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
76 van der Gaag NA, Kloek JJ, de Bakker JK, Musters B, Geskus RB, Busch OR, Bosma A, Gouma DJ, van Gulik TM. Survival analysis and prognostic nomogram for patients undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol. 2012;23:2642-2649. [PMID: 22532585 DOI: 10.1093/annonc/mds077] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 6.0] [Reference Citation Analysis]
77 Moole H, Tathireddy H, Dharmapuri S, Moole V, Boddireddy R, Yedama P, Dharmapuri S, Uppu A, Bondalapati N, Duvvuri A. Success of photodynamic therapy in palliating patients with nonresectable cholangiocarcinoma: A systematic review and meta-analysis. World J Gastroenterol 2017; 23(7): 1278-1288 [PMID: 28275308 DOI: 10.3748/wjg.v23.i7.1278] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 35] [Article Influence: 11.8] [Reference Citation Analysis]
78 Hue JJ, Sugumar K, Markt SC, Mohamed A, Selfridge JE, Bajor D, Rothermel LD, Hardacre JM, Ammori JB, Winter JM, Ocuin LM. Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma. Surgery 2021;169:233-9. [PMID: 33087251 DOI: 10.1016/j.surg.2020.09.011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Conci S, Ruzzenente A, Simbolo M, Bagante F, Rusev B, Isa G, Lawlor RT, Pedrazzani C, Iacono C, Guglielmi A, Scarpa A. Multigene mutational profiling of biliary tract cancer is related to the pattern of recurrence in surgically resected patients. Updates Surg 2020;72:119-28. [PMID: 32020551 DOI: 10.1007/s13304-020-00718-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
80 Zhang W, Yan LN. Perihilar cholangiocarcinoma: Current therapy. World J Gastrointest Pathophysiol 2014; 5(3): 344-354 [PMID: 25133034 DOI: 10.4291/wjgp.v5.i3.344] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
81 Shi Z, Yang MZ, He QL, Ou RW, Chen YT. Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma. World J Gastroenterol 2009; 15(15): 1892-1896 [PMID: 19370789 DOI: 10.3748/wjg.15.1892] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
82 Seehofer D, Kamphues C, Neuhaus P. [Resection of Klatskin tumors]. Chirurg 2012;83:221-8. [PMID: 22406679 DOI: 10.1007/s00104-011-2177-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
83 Romine MM, White J. Role of Transplant in Biliary Disease. Surgical Clinics of North America 2019;99:387-401. [DOI: 10.1016/j.suc.2018.12.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Han IW, Jang JY, Lee KB, Kang MJ, Kwon W, Park JW, Chang YR, Kim SW. Clinicopathological analysis and prognosis of extrahepatic bile duct cancer with a microscopic positive ductal margin. HPB (Oxford) 2014;16:575-81. [PMID: 24308425 DOI: 10.1111/hpb.12193] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
85 Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford) 2014;16:297-303. [PMID: 23981000 DOI: 10.1111/hpb.12150] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
86 Seyama Y, Kokudo N, Makuuchi M. Radical Resection of Biliary Tract Cancers and the Role of Extended Lymphadenectomy. Surgical Oncology Clinics of North America 2009;18:339-59. [DOI: 10.1016/j.soc.2008.12.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Kitamura K, Hatano E, Higashi T, Seo S, Nakamoto Y, Narita M, Taura K, Yasuchika K, Nitta T, Yamanaka K, Doi R, Ikai I, Uemoto S. Prognostic value of (18)F-fluorodeoxyglucose positron emission tomography in patients with extrahepatic bile duct cancer. J Hepatobiliary Pancreat Sci 2011;18:39-46. [PMID: 20503059 DOI: 10.1007/s00534-010-0293-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
88 Khuntikeo N, Pugkhem A, Titapun A, Bhudhisawasdi V. Surgical management of perihilar cholangiocarcinoma: a Khon Kaen experience. J Hepatobiliary Pancreat Sci. 2014;21:521-524. [PMID: 24464976 DOI: 10.1002/jhbp.74] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
89 Lee KJ, Yi SW, Cha J, Seong J, Bang S, Song SY, Kim HM, Park SW. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. Cancer Chemother Pharmacol. 2016;78:841-846. [PMID: 27586966 DOI: 10.1007/s00280-016-3143-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
90 Kobayashi S, Nagano H, Sakai D, Eguchi H, Hatano E, Kanai M, Seo S, Taura K, Fujiwara Y, Ajiki T, Takemura S, Kubo S, Yanagimoto H, Toyokawa H, Tsuji A, Terajima H, Morita S, Ioka T. Phase I study of adjuvant gemcitabine or S-1 in patients with biliary tract cancers undergoing major hepatectomy: KHBO1003 study. Cancer Chemother Pharmacol 2014;74:699-709. [DOI: 10.1007/s00280-014-2543-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
91 Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg. 2009;250:210-218. [PMID: 19638920 DOI: 10.1097/sla.0b013e3181afe0ab] [Cited by in Crossref: 153] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
92 Zhang H, Yang T, Wu M, Shen F. Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management. Cancer Letters 2016;379:198-205. [DOI: 10.1016/j.canlet.2015.09.008] [Cited by in Crossref: 91] [Cited by in F6Publishing: 89] [Article Influence: 18.2] [Reference Citation Analysis]
93 Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol 2011; 2(2): 94-107 [PMID: 21603318 DOI: 10.5306/wjco.v2.i2.94] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
94 Paul A, Kaiser GM, Molmenti EP, Schroeder T, Vernadakis S, Oezcelik A, Baba HA, Cicinnati VR, Sotiropoulos GC. Klatskin Tumors and the Accuracy of the Bismuth-Corlette Classification. The American Surgeon 2011;77:1695-9. [DOI: 10.1177/000313481107701246] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
95 Chen W, Liang J, Huang L, Cai J, Lei Y, Lai J, Liang L, Zhang K. Characterizing the activation of the Wnt signaling pathway in hilar cholangiocarcinoma using a tissue microarray approach. Eur J Histochem 2016;60:2536. [PMID: 26972709 DOI: 10.4081/ejh.2016.2536] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
96 Serrablo A, Tejedor L. Outcome of surgical resection in Klatskin tumors. World J Gastrointest Oncol 2013; 5(7): 147-158 [PMID: 23919109 DOI: 10.4251/wjgo.v5.i7.147] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
97 Hoffmann K, Luible S, Goeppert B, Weiss K, Hinz U, Büchler MW, Schemmer P. Impact of portal vein resection on oncologic long-term outcome in patients with hilar cholangiocarcinoma. Surgery 2015;158:1252-60. [DOI: 10.1016/j.surg.2015.04.032] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
98 Pellino A, Loupakis F, Cadamuro M, Dadduzio V, Fassan M, Guido M, Cillo U, Indraccolo S, Fabris L. Precision medicine in cholangiocarcinoma. Transl Gastroenterol Hepatol 2018;3:40. [PMID: 30148225 DOI: 10.21037/tgh.2018.07.02] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 9.0] [Reference Citation Analysis]
99 Li H, Qin Y, Cui Y, Chen H, Hao X, Li Q. Analysis of the surgical outcome and prognostic factors for hilar cholangiocarcinoma: a Chinese experience. Dig Surg. 2011;28:226-231. [PMID: 21540611 DOI: 10.1159/000327361] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
100 Kobayashi S, Tomokuni A, Gotoh K, Takahashi H, Akita H, Marubashi S, Yamada T, Teshima T, Nishiyama K, Yano M, Ohigashi H, Ishikawa O, Sakon M. Evaluation of the safety and pathological effects of neoadjuvant full-dose gemcitabine combination radiation therapy in patients with biliary tract cancer. Cancer Chemother Pharmacol 2015;76:1191-8. [DOI: 10.1007/s00280-015-2908-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
101 Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K. Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int 2011;10:10-20. [PMID: 21269929 DOI: 10.1016/s1499-3872(11)60001-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
102 Franken LC, Schreuder AM, Roos E, van Dieren S, Busch OR, Besselink MG, van Gulik TM. Morbidity and mortality after major liver resection in patients with perihilar cholangiocarcinoma: A systematic review and meta-analysis. Surgery. 2019;165:918-928. [PMID: 30871811 DOI: 10.1016/j.surg.2019.01.010] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 15.0] [Reference Citation Analysis]
103 Zhang Z, Xing H, Yuan H, Liu K, Zhu J, Su Y, Guo J, Jiang N, Zhang Z. Diagnosis and treatment for advanced hilar cholangiocarcinoma: experience of 24 cases. Front Med China 2008;2:134-8. [DOI: 10.1007/s11684-008-0025-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
104 Howell M, Valle JW. The role of adjuvant chemotherapy and radiotherapy for cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015;29:333-43. [PMID: 25966432 DOI: 10.1016/j.bpg.2015.03.001] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
105 Suriyo T, Fuangthong M, Artpradit C, Ungtrakul T, Sricharunrat T, Taha F, Satayavivad J. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells. Eur J Pharmacol 2021;897:173960. [PMID: 33617828 DOI: 10.1016/j.ejphar.2021.173960] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
106 Liang L, Li C, Jia HD, Diao YK, Xing H, Pawlik TM, Lau WY, Shen F, Huang DS, Zhang CW, Yang T. Prognostic factors of resectable perihilar cholangiocarcinoma: a systematic review and meta-analysis of high-quality studies. Ther Adv Gastrointest Endosc 2021;14:2631774521993065. [PMID: 33629062 DOI: 10.1177/2631774521993065] [Reference Citation Analysis]
107 Ku D, Tang R, Pang T, Pleass H, Richardson A, Yuen L, Lam V. Survival outcomes of hepatic resections in Bismuth-Corlette type IV cholangiocarcinoma. ANZ J Surg 2020;90:1604-14. [PMID: 31840387 DOI: 10.1111/ans.15531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
108 Chauhan A, House MG, Pitt HA, Nakeeb A, Howard TJ, Zyromski NJ, Schmidt CM, Ball CG, Lillemoe KD. Post-operative morbidity results in decreased long-term survival after resection for hilar cholangiocarcinoma. HPB (Oxford). 2011;13:139-147. [PMID: 21241432 DOI: 10.1111/j.1477-2574.2010.00262.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
109 Birgin E, Rasbach E, Reissfelder C, Rahbari NN. A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma. Eur J Surg Oncol 2020;46:747-53. [PMID: 31987703 DOI: 10.1016/j.ejso.2020.01.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
110 Kobayashi S, Tomokuni A, Gotoh K, Takahashi H, Akita H, Marubashi S, Yamada T, Teshima T, Fukui K, Fujiwara Y, Sakon M. A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. European Journal of Surgical Oncology (EJSO) 2017;43:763-71. [DOI: 10.1016/j.ejso.2016.12.008] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
111 Yun BL, Lee JM, Baek JH, Kim SH, Lee JY, Han JK, Choi BI. Radiofrequency ablation for treating liver metastases from a non-colorectal origin. Korean J Radiol 2011;12:579-87. [PMID: 21927559 DOI: 10.3348/kjr.2011.12.5.579] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
112 Yubin L, Chihua F, Zhixiang J, Jinrui O, Zixian L, Jianghua Z, Ye L, Haosheng J, Chaomin L. Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China. Ann Surg Oncol 2008;15:2113-9. [PMID: 18546046 DOI: 10.1245/s10434-008-9932-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 41] [Article Influence: 3.8] [Reference Citation Analysis]
113 Otani K, Chijiiwa K, Kai M, Ohuchida J, Nagano M, Tsuchiya K, Kondo K. Outcome of surgical treatment of hilar cholangiocarcinoma. J Gastrointest Surg. 2008;12:1033-1040. [PMID: 18085342 DOI: 10.1007/s11605-007-0453-z] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
114 Lin YK, Hsieh MC, Wang WW, Lin YC, Chang WW, Chang CL, Cheng YF, Wu SY. Outcomes of adjuvant treatments for resectable intrahepatic cholangiocarcinoma: Chemotherapy alone, sequential chemoradiotherapy, or concurrent chemoradiotherapy. Radiother Oncol 2018;128:575-83. [PMID: 29801723 DOI: 10.1016/j.radonc.2018.05.011] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
115 Murakami Y, Uemura K, Sudo T, Hashimoto Y, Nakashima A, Kondo N, Sakabe R, Kobayashi H, Sueda T. Is para-aortic lymph node metastasis a contraindication for radical resection in biliary carcinoma? World J Surg. 2011;35:1085-1093. [PMID: 21400012 DOI: 10.1007/s00268-011-1036-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
116 Ramírez-Merino N, Aix SP, Cortés-Funes H. Chemotherapy for cholangiocarcinoma: An update. World J Gastrointest Oncol 2013; 5(7): 171-176 [PMID: 23919111 DOI: 10.4251/wjgo.v5.i7.171] [Cited by in CrossRef: 69] [Cited by in F6Publishing: 82] [Article Influence: 8.6] [Reference Citation Analysis]
117 Tan JW, Hu BS, Chu YJ, Tan YC, Ji X, Chen K, Ding XM, Zhang A, Chen F, Dong JH. One-stage resection for Bismuth type IV hilar cholangiocarcinoma with high hilar resection and parenchyma-preserving strategies: a cohort study. World J Surg 2013;37:614-21. [PMID: 23283218 DOI: 10.1007/s00268-012-1878-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
118 Zhao Q, Qian S, Zhu L, Qu XD, Zhang W, Yan ZP, Cheng JM, Liu QX, Liu R, Wang JH. Transcatheter arterial chemoembolization with gemcitabine and oxaliplatin for the treatment of advanced biliary tract cancer. Onco Targets Ther 2015;8:595-600. [PMID: 25792843 DOI: 10.2147/OTT.S79316] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
119 Fu Z, Ma K, Dong B, Zhao C, Che C, Dong C, Zhang R, Wang H, Wang X, Liang R. The synergistic antitumor effect of Huaier combined with 5-Florouracil in human cholangiocarcinoma cells. BMC Complement Altern Med 2019;19:203. [PMID: 31391034 DOI: 10.1186/s12906-019-2614-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
120 Zhou T, Liu L, Dai HS, Zhang CC, He Y, Zhang LD, Li DJ, Bie P, Ding J, Chen ZY; other members of the Hilar Cholangiocarcinoma Study Group. Impact of body mass index on postoperative outcomes in patients undergoing radical resection for hilar cholangiocarcinoma. J Surg Oncol 2020;122:1418-25. [PMID: 32794267 DOI: 10.1002/jso.26172] [Reference Citation Analysis]
121 Heimbach JK. Successful liver transplantation for hilar cholangiocarcinoma: . Current Opinion in Gastroenterology 2008;24:384-8. [DOI: 10.1097/mog.0b013e3282f706ce] [Cited by in Crossref: 26] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
122 Kim K, Chie EK, Jang J, Kim SW, Han S, Oh D, Im S, Kim T, Bang Y, Ha SW. Distant Metastasis Risk Stratification for Patients Undergoing Curative Resection Followed by Adjuvant Chemoradiation for Extrahepatic Bile Duct Cancer. International Journal of Radiation Oncology*Biology*Physics 2012;84:81-7. [DOI: 10.1016/j.ijrobp.2011.10.059] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
123 Frosio F, Mocchegiani F, Conte G, Bona ED, Vecchi A, Nicolini D, Vivarelli M. Neoadjuvant therapy in the treatment of hilar cholangiocarcinoma: Review of the literature. World J Gastrointest Surg 2019; 11(6): 279-286 [PMID: 31367275 DOI: 10.4240/wjgs.v11.i6.279] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
124 Zhou W, Qian L, Rong Y, Zhou Q, Shan J, Li P, Shi L, Liu H, Sun X. Prognostic factors and patterns of recurrence after curative resection for patients with distal cholangiocarcinoma. Radiotherapy and Oncology 2020;147:111-7. [DOI: 10.1016/j.radonc.2020.03.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]